Weight Loss Drug Competition - FDA Approves Expanded Use Of Eli Lilly's Blockbuster Tirzepatide For Weight Loss, Undercutting Novo Nordisk's Price
Portfolio Pulse from Vandana Singh
The FDA has approved Eli Lilly's Zepbound (tirzepatide) injection for obesity treatment, which is expected to be available in the U.S. by the end of the year. The drug is priced approximately 20% lower than Nova Nordisk's semaglutide 2.4 mg injection for weight loss. Eli Lilly's shares are up 1.99% following the news.
November 08, 2023 | 7:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's Zepbound has been approved by the FDA for obesity treatment. The drug is priced lower than its competitor, potentially increasing its market share. Eli Lilly's shares rose 1.99% following the news.
The FDA approval of Zepbound for obesity treatment expands Eli Lilly's product portfolio and potentially increases its market share due to the lower price. This positive news likely contributed to the rise in Eli Lilly's share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Eli Lilly's Zepbound, a competitor to Nova Nordisk's semaglutide 2.4 mg injection for weight loss, has been approved by the FDA and is priced 20% lower.
The FDA approval of Eli Lilly's Zepbound, which is priced 20% lower than Nova Nordisk's semaglutide 2.4 mg injection, could potentially impact Nova Nordisk's market share and revenues in the obesity treatment market.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70